ACAD
27.755
-1.255
-4.326%
AEMD
2.192
+0.012
+0.5550%
APRI
1.07
0.00
0.00%
ARNA
15.11
+0.03
+0.20%
ATEC
1.808
-0.042
-2.2595%
CNAT
5.39
-0.2
-3.58%
CRXM
0.175
0.00
0.00%
CYTX
1.13
+0.05
+4.6204%
DXCM
74.625
-3.125
-4.019%
GNMK
12.315
-0.275
-2.184%
HALO
14.22
-0.37
-2.54%
ILMN
177.58
-3.31
-1.83%
INNV
0.115
-0.005
-4.087%
INO
8.22
-0.16
-1.91%
ISCO
1.15
+0.02
+1.77%
ISIS
57.56
0.00
0.00%
LGND
120.822
-1.488
-1.217%
LPTN
2.93
-0.08
-2.66%
MBVX
1.44
-0.02
-1.37%
MEIP
2.32
-0.02
-0.85%
MNOV
5.29
-0.17
-3.11%
MRTX
3.925
-0.125
-3.086%
MSTX
0.131
-0.007
-5.278%
NBIX
45.828
-1.482
-3.1334%
NUVA
75.151
-1.539
-2.007%
ONCS
1.15
+0.04
+3.60%
ONVO
2.703
-0.038
-1.3686%
OREX
3.06
+0.03
+0.99%
OTIC
18.55
-0.4
-2.11%
QDEL
27.38
+0.05
+0.18%
RCPT
231.96
0.00
0.00%
RGLS
1.045
+0.025
+2.451%
RMD
77.4
-0.29
-0.37%
SCIE
0
0.00
-23.0769%
SPHS
2.361
+0.251
+11.8910%
SRNE
2.075
-0.025
-1.190%
TROV
1.05
-0.07
-6.2411%
VICL
2.512
+0.032
+1.2944%
VOLC
18
0.00
0.00%
ZGNX
14.5
-0.25
-1.69%
ACAD
27.755
-1.255
-4.326%
AEMD
2.192
+0.012
+0.5550%
APRI
1.07
0.00
0.00%
ARNA
15.11
+0.03
+0.20%
ATEC
1.808
-0.042
-2.2595%
CNAT
5.39
-0.2
-3.58%
CRXM
0.175
0.00
0.00%
CYTX
1.13
+0.05
+4.6204%
DXCM
74.625
-3.125
-4.019%
GNMK
12.315
-0.275
-2.184%
HALO
14.22
-0.37
-2.54%
ILMN
177.58
-3.31
-1.83%
INNV
0.115
-0.005
-4.087%
INO
8.22
-0.16
-1.91%
ISCO
1.15
+0.02
+1.77%
ISIS
57.56
0.00
0.00%
LGND
120.822
-1.488
-1.217%
LPTN
2.93
-0.08
-2.66%
MBVX
1.44
-0.02
-1.37%
MEIP
2.32
-0.02
-0.85%
MNOV
5.29
-0.17
-3.11%
MRTX
3.925
-0.125
-3.086%
MSTX
0.131
-0.007
-5.278%
NBIX
45.828
-1.482
-3.1334%
NUVA
75.151
-1.539
-2.007%
ONCS
1.15
+0.04
+3.60%
ONVO
2.703
-0.038
-1.3686%
OREX
3.06
+0.03
+0.99%
OTIC
18.55
-0.4
-2.11%
QDEL
27.38
+0.05
+0.18%
RCPT
231.96
0.00
0.00%
RGLS
1.045
+0.025
+2.451%
RMD
77.4
-0.29
-0.37%
SCIE
0
0.00
-23.0769%
SPHS
2.361
+0.251
+11.8910%
SRNE
2.075
-0.025
-1.190%
TROV
1.05
-0.07
-6.2411%
VICL
2.512
+0.032
+1.2944%
VOLC
18
0.00
0.00%
ZGNX
14.5
-0.25
-1.69%
Home » Archive by Category

Xconomy

If Budget Holds, NIH Precision Study Could Be Flush As Volunteers Arrive

May 4, 2017 – 2:30 am

Until this week, many U.S. government science agencies and programs seemed destined for a big haircut, plus the loss of a limb or two. That included the Precision Medicine Initiative, an ambitious…

[[Click headline to continue reading.]]

New San Diego Biotech Looks to Open Way for Anti-Cancer Drugs

May 3, 2017 – 4:00 am

In early 2002, the Finnish-born scientist Erkki Ruoslahti stepped down as CEO of what is now San Diego’s Sanford Burnham Prebys Medical Discovery Institute. He moved to Santa Barbara, CA, where he…

[[Click headline to continue reading.]]

CA Stem Cell Agency Chief Randy Mills to Leave After Three Years

May 2, 2017 – 11:58 am

[Updated 5/2/17, 7:30 p.m. ET. See below.] The head of California’s stem-cell agency is stepping down after three years on the job. C. Randall Mills, known as Randy, is leaving the agency to…

[[Click headline to continue reading.]]

Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

April 30, 2017 – 8:44 pm

When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well…

[[Click headline to continue reading.]]

Bio Roundup: Trumpcare Flails, Spinraza Sales, Batten OK & More

April 28, 2017 – 2:30 am

To judge the first 100 days of a new administration is, as many pundits have pointed out, an odd vestige of history, more convenient than significant. Which is why we’ll start this week’s…

[[Click headline to continue reading.]]

Gottlieb’s FDA Nomination Gets Committee Nod, Advances to Senate

April 27, 2017 – 7:53 am

Scott Gottlieb’s nomination to the top post of the FDA is on its way to the full U.S. Senate. The Senate Health, Education, Labor & Pensions Committee voted 14-9 on Thursday to approve Gottlieb’s…

[[Click headline to continue reading.]]

Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug?

April 26, 2017 – 9:30 am

Four months after its drug nusinersen (Spinraza) became the first ever approved to treat the rare genetic disease spinal muscular atrophy, Biogen (NASDAQ: BIIB) released study results Tuesday that…

[[Click headline to continue reading.]]

Forge Therapeutics Raises $15M to Take on Drug-Resistant Superbugs

April 25, 2017 – 11:06 am

One reason that drug-resistant “superbugs” are a growing healthcare problem is the hardiness of gram-negative bacteria, a type of bacteria whose characteristics render many antibiotics ineffective….

[[Click headline to continue reading.]]

While You Were Sleeping: ResMed Builds an Empire in the Cloud

April 25, 2017 – 5:00 am

Over the past 28 years or so, ResMed (NYSE: RMD) has built an empire around its respiratory devices for managing sleep apnea and other forms of “sleep-disordered breathing.” In the fiscal year that…

[[Click headline to continue reading.]]

Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal

April 23, 2017 – 9:27 pm

In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24 billion to tap into the growing markets for…

[[Click headline to continue reading.]]